DURHAM, N.C., July 27, 2022 /PRNewswire/ — Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount. The acquisition is the first in a series of deals lined up across the UK and Germany, as the company grows its network of integrated … Read more
Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, including a tech hub in Hyderabad, India. Meridian is a multi-specialty … Read more
In 2022 Velocity undertook its first national survey in the U.S. of patients who have previously taken part in clinical research, receiving 1,129 responses. We wanted to gauge views and attitudes on taking part in clinical research, including thoughts regarding decentralization and the use of technology. The results led us to three key insights and … Read more
Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces it has acquired MedPharmics, a multi-site company based in the US. The acquisition brings Velocity’s total number of locations to 40 sites across 19 U.S. states and Europe. With this acquisition, Velocity will add just over 100 employees of diversified backgrounds to the … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the Moderna press release >
Meridian Clinical Research, now part of Velocity Clinical Research, won the first ever Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS). The award was presented to Meridian at the 2021 Global Site Solutions Summit in Hollywood, FL. Sponsored by Sanofi, the award was created to, “Celebrate a clinical research site … Read more
Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research (now part of Velocity Clinical Research) in Savannah, GA. Following a tour of the company’s internal medicine site in Savannah, the group held a roundtable to discuss patient recruitment efforts and the research conducted for COVID-19 vaccine clinical … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. The company was also part of Platinum Research Network, which won the ViE award for Best Clinical Trial Network. “It’s incredible to earn these awards when vaccine trials are the industry’s priority and … Read more
Brandon Essink, MD, CPI, is a co-principal investigator for the Phase 3 clinical trial of Moderna’s COVID-19 vaccine. Read the full National Institutes of Health (NIH) press release: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
The first participant in the Moderna Phase 3 COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s (now Velcoity Clinical Research) internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine candidate (mRNA-1273) against COVID-19. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid